


CLAIMS:

1. A compound of the general formula (I):

5



wherein

R' represents an anti-epileptic (AED), anticonvulsive, neuroprotective,

10 neurotransmitter, or nootrope moiety;

R is selected from the group consisting of -CH₂OH, -CHO and -CH₂NH₂;
and pharmaceutically acceptable salts thereof.

2. The compound according to claim 1, wherein R' is an anti-epileptic drug
15 moiety.

3. The compound according to claim 2, wherein said anti-epileptic drug is
selected from the group consisting of phenytoin or other hydantoins; phenobarbital
or other barbiturates, primidone, carbamazepine and oxacarbamazepine, valproic
20 acid or its derivatives; oxazolidines; benzo-diazepines; felbamate, gabapentin,
lamotrigine, vigabatrin and adrenocorticotrophic hormone (ACTH).

4. The compound according to claim 1, wherein R' represents a moiety of
γ-aminobutyric acid and/or kynurenic acid.

25

5. A composition comprising a physical mixture of:

(a) at least one substance selected from the group consisting of pyridoxal,
pyridoxamine and pyridoxine, their pharmaceutically acceptable functional
derivatives and salts thereof; and

- 30 (b) at least one AED, anticonvulsive, neuroprotective drug or nootrope
compound.

6. The composition according to claim 5, wherein component (b) is an anti-epileptic drug.

5 7. The composition according to claim 6, wherein said anti-epileptic drug is selected from the group consisting of phenytoin or other hydantoins; phenobarbital or other barbiturates, primidone, carbamazepine and oxacarbamazepine, valproic acid or its derivatives; oxazolidines; benzo-diazepines; felbamate, gabapentin, lamotrigine, vigabatrin and adrenocorticotrophic hormone (ACTH).

10

8. A pharmaceutical composition comprising a therapeutically effective amount of the compound of the general formula (I) and a pharmaceutically acceptable carrier or excipient.

15 9. The pharmaceutical composition according to claim 8, wherein the compound of the general formula (I) having R' in an amount which is no greater than the maximal safe amount for a single administration of the attached anti-epileptic (AED), anticonvulsive, neuroprotective, neurotransmitter, or nootrope component.

20

10. A pharmaceutical composition comprising therapeutically effective amounts of components (a) and (b) as defined above in Claim 5, and at least one pharmaceutically acceptable carrier, diluent, or excipient.

25 11. The pharmaceutical composition according to claim 10, wherein components (a) and (b) are present in dosages no greater than their respective maximal safe dosages for a single administration.

12. A method of treatment of a neurological disease or disorder comprising
30 administering to an individual in need thereof a therapeutically effective amount of a compound of the general formula (I).

13. A method of treatment of a neurological disease or disorder comprising administering to an individual in need thereof a therapeutically effective amount of a composition in accordance with claim 5.
- 5 14. A method of treatment of a neurological disease or disorder comprising co-administering to an individual in need thereof a therapeutically effective amounts of components (a) and (b) as defined in claim 5, in separate compositions.
- 10 15. The method according to any one of claims 12 to 14, wherein said neurological disease or disorder is epilepsy.
16. A method for preventing epileptic episodes, alleviating epileptic episodes and/or reducing side effects of AEDs comprising the step of administering to a
15 subject a therapeutically effective amount of a compound of the general formula (I).
17. A method for preventing epileptic episodes, alleviating epileptic episodes and/or reducing side effects of AEDs comprising the step of administering to a subject:
- 20 (a) at least one substance selected from the group consisting of pyridoxal, pyridoxamine and pyridoxine, their pharmaceutically acceptable functional derivatives and salts thereof, in an amount which is equivalent to from about 2 to about 500 times the recommended daily dietary allowance of pyridoxine; in combination with
- 25 (b) at least one AED, anticonvulsive, neuroprotective drug or nootrope compound.
18. The method according to any one of claims 12 to 17, wherein said compound or composition is orally administered.

30

19. Use of a compound of the general formula (I) for the preparation of a pharmaceutical composition.
20. The use according to Claim 19, wherein said pharmaceutical
5 composition is for the treatment of epilepsy.